Cargando…

Target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)

BACKGROUND: Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) is a highly effective way to reduce virus transmission. There have been increasing calls to improve access to PrEP in Canada. One way to improve access is by having more prescribers available. The objective of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: MacDonald, Calum B., Murphy, Andrea L., Isenor, Jennifer E., Ramsey, Tasha D., Furlotte, Kirk, Smith, Alesha J., Bishop, Andrea, Kelly, Deborah V., Woodill, Lisa, Booker, Connor, Wilby, Kyle John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331363/
https://www.ncbi.nlm.nih.gov/pubmed/37435507
http://dx.doi.org/10.1177/17151635231177027
_version_ 1785070241442693120
author MacDonald, Calum B.
Murphy, Andrea L.
Isenor, Jennifer E.
Ramsey, Tasha D.
Furlotte, Kirk
Smith, Alesha J.
Bishop, Andrea
Kelly, Deborah V.
Woodill, Lisa
Booker, Connor
Wilby, Kyle John
author_facet MacDonald, Calum B.
Murphy, Andrea L.
Isenor, Jennifer E.
Ramsey, Tasha D.
Furlotte, Kirk
Smith, Alesha J.
Bishop, Andrea
Kelly, Deborah V.
Woodill, Lisa
Booker, Connor
Wilby, Kyle John
author_sort MacDonald, Calum B.
collection PubMed
description BACKGROUND: Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) is a highly effective way to reduce virus transmission. There have been increasing calls to improve access to PrEP in Canada. One way to improve access is by having more prescribers available. The objective of this study was to determine target users’ acceptance of a PrEP-prescribing service by pharmacists in Nova Scotia. METHODS: A triangulation, mixed-methods study was conducted consisting of an online survey and qualitative interviews underpinned by the Theoretical Framework of Acceptability (TFA) constructs (affective attitude, burden, ethicality, intervention coherence, opportunity cost, perceived effectiveness and self-efficacy). Participants were those eligible for PrEP in Nova Scotia (men who have sex with men or transgender women, persons who inject drugs and HIV-negative individuals in serodiscordant relationships). Descriptive statistics and ordinal logistic regression were used to analyze survey data. Interview data were deductively coded according to each TFA construct and then inductively coded to determine themes within each construct. RESULTS: A total of 148 responses were captured by the survey, and 15 participants were interviewed. Participants supported pharmacists’ prescribing PrEP across all TFA constructs from both survey and interview data. Identified concerns related to pharmacists’ abilities to order and view lab results, pharmacists’ knowledge and skills for sexual health and the potential for experiencing stigma within pharmacy settings. CONCLUSION: A pharmacist-led PrEP-prescribing service is acceptable to eligible populations in Nova Scotia. The feasibility of PrEP prescribing by pharmacists should be pursued as an intervention to increase access to PrEP.
format Online
Article
Text
id pubmed-10331363
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-103313632023-07-11 Target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) MacDonald, Calum B. Murphy, Andrea L. Isenor, Jennifer E. Ramsey, Tasha D. Furlotte, Kirk Smith, Alesha J. Bishop, Andrea Kelly, Deborah V. Woodill, Lisa Booker, Connor Wilby, Kyle John Can Pharm J (Ott) Research and Clinical BACKGROUND: Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) is a highly effective way to reduce virus transmission. There have been increasing calls to improve access to PrEP in Canada. One way to improve access is by having more prescribers available. The objective of this study was to determine target users’ acceptance of a PrEP-prescribing service by pharmacists in Nova Scotia. METHODS: A triangulation, mixed-methods study was conducted consisting of an online survey and qualitative interviews underpinned by the Theoretical Framework of Acceptability (TFA) constructs (affective attitude, burden, ethicality, intervention coherence, opportunity cost, perceived effectiveness and self-efficacy). Participants were those eligible for PrEP in Nova Scotia (men who have sex with men or transgender women, persons who inject drugs and HIV-negative individuals in serodiscordant relationships). Descriptive statistics and ordinal logistic regression were used to analyze survey data. Interview data were deductively coded according to each TFA construct and then inductively coded to determine themes within each construct. RESULTS: A total of 148 responses were captured by the survey, and 15 participants were interviewed. Participants supported pharmacists’ prescribing PrEP across all TFA constructs from both survey and interview data. Identified concerns related to pharmacists’ abilities to order and view lab results, pharmacists’ knowledge and skills for sexual health and the potential for experiencing stigma within pharmacy settings. CONCLUSION: A pharmacist-led PrEP-prescribing service is acceptable to eligible populations in Nova Scotia. The feasibility of PrEP prescribing by pharmacists should be pursued as an intervention to increase access to PrEP. SAGE Publications 2023-06-12 /pmc/articles/PMC10331363/ /pubmed/37435507 http://dx.doi.org/10.1177/17151635231177027 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research and Clinical
MacDonald, Calum B.
Murphy, Andrea L.
Isenor, Jennifer E.
Ramsey, Tasha D.
Furlotte, Kirk
Smith, Alesha J.
Bishop, Andrea
Kelly, Deborah V.
Woodill, Lisa
Booker, Connor
Wilby, Kyle John
Target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title Target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_full Target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_fullStr Target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_full_unstemmed Target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_short Target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_sort target users’ acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (prep) for human immunodeficiency virus (hiv)
topic Research and Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331363/
https://www.ncbi.nlm.nih.gov/pubmed/37435507
http://dx.doi.org/10.1177/17151635231177027
work_keys_str_mv AT macdonaldcalumb targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT murphyandreal targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT isenorjennifere targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT ramseytashad targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT furlottekirk targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT smithaleshaj targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT bishopandrea targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT kellydeborahv targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT woodilllisa targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT bookerconnor targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT wilbykylejohn targetusersacceptanceofapharmacistledprescribingserviceforpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv